Application Serial No. 10/003,463 Amendment After Final dated 10 March 2010 Reply to Office Action dated 10 December 2009

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

Claim 1 (currently amended): A <u>pharmaceutical</u> vaeeine composition that potentiates immunogenicity of low immunogenic antigens, comprising:

(A) one or more low immunogenic antigens selected from the group consisting of peptides, polypeptides, proteins and their corresponding nucleic acid sequences; and

(B) an immunogenic potentiating effective amount of a vaccine carrier consisting of very small size protoilposomes (VSSPs), wherein the VSSPs are derived from the Outer Membrane Protein Complex (OMPC) of Neisseria meningitidis wherein gangliosides have been incorporated into the OMPC.

wherein the antigen is not structurally changed by chemical protein conjugation and is not incorporated into the VSSPs and wherein the vaccine carrier stimulates and potentiates both humoral and cellular immune responses against the antigen.

Claim 2 (canceled).

Claim 3 (previously presented): The composition of claim 1, wherein the low immunogenic antigens are growth factor receptors or their extra-cellular domains.

Claim 4 (previously presented): The composition of claim 3, wherein the extra-cellular domains of the growth factors receptors may or may not contain the trans-membrane region.

Application Serial No. 10/003,463 Amendment After Final dated 10 March 2010 Reply to Office Action dated 10 December 2009

Claim 5 (previously presented): The composition of claims 3, wherein the growth factor receptors are HER-1, HER-2, PDGR-R or any variation containing the extra-cellular domain, with or without the trans-membrane region.

Claim 6 (previously presented): The composition of claim 1, wherein the *Netsseria* meningitidis is either a wild type or a genetically modified strain.

Claim 7 (previously presented): The composition of claim 1, wherein the VSSPs are obtained by hydrophobically incorporating the gangliosides into the OMPC.

Claim 8 (previously presented): The composition of claim 7, wherein the gangliosides are GM1, GM3, their N-acetylated variations or their N-glycolylated variations.

Claim 9 (previously presented): The composition of claim 27, wherein the adjuvant is an oily adjuvant, or a natural or recombinant polypeptide.

Claim 10 (previously presented): The composition of claim 9, wherein the oily adjuvant is the Incomplete Freund's Adjuvant.

Claim 11 (previously presented): The composition of claim 10, wherein the Incomplete Freund's Adjuvant is Montanide ISA 51.

Claims 12-26 (canceled).

Claim 27 (previously presented): The composition of claim 1, wherein the composition further comprises one or more adjuvants.

Application Serial No. 10/003,463 Amendment After Final dated 10 March 2010 Reply to Office Action dated 10 December 2009

 ${\it Claim}~28~(previously~presented); The composition~of~claim~8, wherein~the~gangliosides~are~N-acetylated~GM3.$

Claim 29 (previously presented): The composition of claim 5, wherein the growth factor receptor is HER-1.